{
  "exams": [
    {
      "id": "womens-health",
      "name": "Women's Health",
      "shortName": "Women's Health",
      "totalSteps": 45,
      "steps": [
        {
          "id": "wh-1",
          "stepNumber": 1,
          "title": "What is the mechanism of action of Combined Hormonal Contraceptives (CHC)?",
          "pageRef": "p.2",
          "comments": [
            "Progestins (primary): thicken cervical mucus, slow tubal motility, induce endometrial atrophy, block LH surge, suppress FSH",
            "Estrogen: stabilize endometrial lining, provide cycle control"
          ]
        },
        {
          "id": "wh-2",
          "stepNumber": 2,
          "title": "What are the ACHES warning signs for serious COC adverse effects?",
          "pageRef": "p.4",
          "subSteps": [
            {
              "id": "2a",
              "content": "A - Abdominal pain (severe)"
            },
            {
              "id": "2b",
              "content": "C - Chest pain, shortness of breath"
            },
            {
              "id": "2c",
              "content": "H - Headache (severe), vision changes"
            },
            {
              "id": "2d",
              "content": "E - Eye problems (vision loss, diplopia)"
            },
            {
              "id": "2e",
              "content": "S - Severe leg pain/swelling"
            }
          ],
          "comments": [
            "Stop CHC immediately if any occur"
          ]
        },
        {
          "id": "wh-3",
          "stepNumber": 3,
          "title": "What medications decrease COC effectiveness?",
          "pageRef": "p.5",
          "comments": [
            "Rifampin (major)",
            "Anticonvulsants: phenobarbital, carbamazepine, phenytoin, lamotrigine",
            "HIV antiretrovirals",
            "St. John's Wort",
            "Tetracyclines, penicillins (case reports)"
          ]
        },
        {
          "id": "wh-4",
          "stepNumber": 4,
          "title": "What are the starting methods for COC?",
          "pageRef": "p.3",
          "subSteps": [
            {
              "id": "4a",
              "content": "First day of cycle - start day 1, backup 7 days"
            },
            {
              "id": "4b",
              "content": "First Sunday - start first Sunday after cycle begins, backup 7 days"
            },
            {
              "id": "4c",
              "content": "Quick start - start day of office visit, backup 7 days (most successful)"
            }
          ]
        },
        {
          "id": "wh-5",
          "stepNumber": 5,
          "title": "How do you manage missed COC doses?",
          "pageRef": "p.6",
          "subSteps": [
            {
              "id": "5a",
              "content": "1 tablet: take ASAP, continue rest as prescribed"
            },
            {
              "id": "5b",
              "content": "\u22652 tablets: take 1 missed tablet ASAP, discard others, continue"
            },
            {
              "id": "5c",
              "content": "If missed in last week: finish active tablets, skip hormone-free interval, start new pack"
            },
            {
              "id": "5d",
              "content": "Use backup contraception until 7 consecutive days of active tablets"
            }
          ]
        },
        {
          "id": "wh-6",
          "stepNumber": 6,
          "title": "What are the contraindications for CHC in patients >35 years old?",
          "pageRef": "p.7",
          "comments": [
            "Do NOT use if >35 yo with:",
            "- Migraine with aura",
            "- Uncontrolled hypertension",
            "- Smoking",
            "- Diabetes with vascular disease"
          ]
        },
        {
          "id": "wh-7",
          "stepNumber": 7,
          "title": "When are CHC contraindicated in smokers?",
          "pageRef": "p.7-8",
          "comments": [
            "Contraindicated: >35 yo and smoke \u226515 cigarettes/day",
            "COC \u226550 mcg EE associated with MI in smokers",
            "Consider progestin-only or nonhormonal alternatives"
          ]
        },
        {
          "id": "wh-8",
          "stepNumber": 8,
          "title": "What are the blood pressure contraindications for CHC?",
          "pageRef": "p.8",
          "subSteps": [
            {
              "id": "8a",
              "content": "Contraindication: SBP \u2265160 or DBP \u2265100"
            },
            {
              "id": "8b",
              "content": "Risk>benefit: SBP 140-159 or DBP 90-99"
            },
            {
              "id": "8c",
              "content": "CHC can increase BP 6-8 mmHg"
            },
            {
              "id": "8d",
              "content": "BP usually normalizes 3-6 months after D/C"
            }
          ]
        },
        {
          "id": "wh-9",
          "stepNumber": 9,
          "title": "What are the transdermal contraceptive options and their administration?",
          "pageRef": "p.6",
          "subSteps": [
            {
              "id": "9a",
              "content": "Xulane: 35 mcg EE + 150 mcg norelgestromin (effective if <90 kg)"
            },
            {
              "id": "9b",
              "content": "Twirla: 30 mcg EE + 120 mcg levonorgestrel (recommended BMI <30)"
            },
            {
              "id": "9c",
              "content": "Apply to abdomen, buttocks, upper torso, or upper arm"
            },
            {
              "id": "9d",
              "content": "Change weekly x3 weeks, then week 4 patch-free"
            }
          ],
          "comments": [
            "~60% more estrogen exposure than 35 mcg COC \u2192 increased thrombotic risk"
          ]
        },
        {
          "id": "wh-10",
          "stepNumber": 10,
          "title": "What are the vaginal ring options and their administration?",
          "pageRef": "p.7",
          "subSteps": [
            {
              "id": "10a",
              "content": "NuvaRing: 15 mcg/day EE + 120 mcg/day etonogestrel - use 3 weeks, discard"
            },
            {
              "id": "10b",
              "content": "Annovera: 13 mcg EE + 150 mcg segesterone - use 3 weeks x13 cycles (reuse)"
            },
            {
              "id": "10c",
              "content": "Insert on/before day 5, remains 3 weeks, remove 1 week"
            },
            {
              "id": "10d",
              "content": "Annovera: avoid tampons (NuvaRing okay with tampons)"
            }
          ]
        },
        {
          "id": "wh-11",
          "stepNumber": 11,
          "title": "What are the oral progestin-only contraceptive options?",
          "pageRef": "p.9-10",
          "subSteps": [
            {
              "id": "11a",
              "content": "Mini pills: Norethindrone 0.35 mg or Norgestrel 0.075 mg (Opill OTC)"
            },
            {
              "id": "11b",
              "content": "Must take same time daily; if >3 hours late: backup x48 hours"
            },
            {
              "id": "11c",
              "content": "Drospirenone 4 mg (Slynd): 24 days active + 4 placebo"
            },
            {
              "id": "11d",
              "content": "Drospirenone: less strict timing, missed = >24 hours late"
            }
          ]
        },
        {
          "id": "wh-12",
          "stepNumber": 12,
          "title": "What is Depo-Provera (DMPA) and its administration?",
          "pageRef": "p.10",
          "subSteps": [
            {
              "id": "12a",
              "content": "150 mg/mL IM (gluteal/deltoid) q3 months"
            },
            {
              "id": "12b",
              "content": "104 mg SubQ (abdomen/thigh) q3 months"
            },
            {
              "id": "12c",
              "content": "If >13 weeks (IM) or >14 weeks (SubQ) \u2192 pregnancy test required"
            },
            {
              "id": "12d",
              "content": "Return to fertility: ~10 months"
            }
          ],
          "comments": [
            "Lower failure rates than CHC",
            "Mainly suppresses ovulation"
          ]
        },
        {
          "id": "wh-13",
          "stepNumber": 13,
          "title": "What are the key adverse effects of Depo-Provera?",
          "pageRef": "p.10",
          "subSteps": [
            {
              "id": "13a",
              "content": "Most frequent: menstrual irregularities (spotting, prolonged bleeding, amenorrhea)"
            },
            {
              "id": "13b",
              "content": "Weight gain: avg 1 kg annually, resolves 6-8 months after last injection"
            },
            {
              "id": "13c",
              "content": "BLACK BOX WARNING: Short-term bone loss"
            },
            {
              "id": "13d",
              "content": "Continue >2 years ONLY if other methods inadequate"
            },
            {
              "id": "13e",
              "content": "Not recommended with long-term corticosteroids"
            }
          ]
        },
        {
          "id": "wh-14",
          "stepNumber": 14,
          "title": "What is Nexplanon and its characteristics?",
          "pageRef": "p.11",
          "subSteps": [
            {
              "id": "14a",
              "content": "4 cm long subdermal implant, 68 mg etonogestrel"
            },
            {
              "id": "14b",
              "content": "Releases 60 mcg/day first month \u2192 30 mcg/day at 3 years"
            },
            {
              "id": "14c",
              "content": "Duration: up to 3 years"
            },
            {
              "id": "14d",
              "content": "Placed in upper arm by trained clinician"
            },
            {
              "id": "14e",
              "content": "Fertility returns within 30 days of removal"
            }
          ],
          "comments": [
            "Efficacy may decrease if >130% ideal body weight"
          ]
        },
        {
          "id": "wh-15",
          "stepNumber": 15,
          "title": "What are the IUD options available?",
          "pageRef": "p.11",
          "subSteps": [
            {
              "id": "15a",
              "content": "Copper IUD (ParaGard): 10 years, 99% effective"
            },
            {
              "id": "15b",
              "content": "Liletta & Mirena: up to 8 years, 20 mcg/day levonorgestrel"
            },
            {
              "id": "15c",
              "content": "Kyleena: up to 5 years, 17.5 mcg/day levonorgestrel"
            },
            {
              "id": "15d",
              "content": "Skyla: up to 3 years, 14 mcg/day levonorgestrel"
            }
          ]
        },
        {
          "id": "wh-16",
          "stepNumber": 16,
          "title": "When should IUDs NOT be inserted?",
          "pageRef": "p.11",
          "comments": [
            "Current pregnancy, PID, STI/STD",
            "Postabortion sepsis, cervicitis",
            "Undiagnosed abnormal vaginal bleeding",
            "Malignancy of genital tract",
            "Uterine anomalies/fibroids distorting cavity",
            "Wilson's disease (copper IUD only)"
          ]
        },
        {
          "id": "wh-17",
          "stepNumber": 17,
          "title": "What are the emergency contraception options?",
          "pageRef": "p.12-13",
          "subSteps": [
            {
              "id": "17a",
              "content": "Levonorgestrel: 1.5 mg x1 within 72 hours (OTC for all ages)"
            },
            {
              "id": "17b",
              "content": "Ulipristal: 30 mg x1 within 120 hours (prescription only)"
            },
            {
              "id": "17c",
              "content": "Copper IUD (most effective)"
            },
            {
              "id": "17d",
              "content": "Does NOT disrupt existing pregnancy"
            }
          ],
          "comments": [
            "Earlier = better efficacy",
            "Implantation usually takes ~5 days after intercourse"
          ]
        },
        {
          "id": "wh-18",
          "stepNumber": 18,
          "title": "What are the key differences between levonorgestrel and ulipristal for emergency contraception?",
          "pageRef": "p.12-13",
          "subSteps": [
            {
              "id": "18a",
              "content": "Levonorgestrel: OTC, within 72 hours, regimen of choice"
            },
            {
              "id": "18b",
              "content": "Ulipristal: Prescription, within 120 hours (5 days)"
            },
            {
              "id": "18c",
              "content": "Ulipristal: not recommended if breastfeeding"
            },
            {
              "id": "18d",
              "content": "Ulipristal: may interfere with hormonal contraception, barrier method x1 month"
            }
          ]
        },
        {
          "id": "wh-19",
          "stepNumber": 19,
          "title": "What is the medication regimen for early pregnancy termination?",
          "pageRef": "p.13",
          "subSteps": [
            {
              "id": "19a",
              "content": "For pregnancy \u226470 days"
            },
            {
              "id": "19b",
              "content": "Mifepristone 200 mg day 1"
            },
            {
              "id": "19c",
              "content": "Misoprostol 800 mcg buccally 24-48 hours later"
            },
            {
              "id": "19d",
              "content": "Higher efficacy earlier in pregnancy"
            }
          ],
          "comments": [
            "Mifepristone: BBW for infection and bleeding",
            "Misoprostol AE: stomach upset, diarrhea, headache, chills, fever"
          ]
        },
        {
          "id": "wh-20",
          "stepNumber": 20,
          "title": "What are the stages and timing of menopause?",
          "pageRef": "p.14",
          "subSteps": [
            {
              "id": "20a",
              "content": "Perimenopause: transition period, irregular cycles"
            },
            {
              "id": "20b",
              "content": "Menopause: \u226512 months after last menses"
            },
            {
              "id": "20c",
              "content": "Postmenopause: period after menopause"
            },
            {
              "id": "20d",
              "content": "Average age: 51 years (range 40-58)"
            }
          ],
          "comments": [
            "Natural life stage, not a disease",
            "Permanent end from loss of ovarian follicle activity"
          ]
        },
        {
          "id": "wh-21",
          "stepNumber": 21,
          "title": "What are the vasomotor symptoms of menopause and their management?",
          "pageRef": "p.14-15",
          "subSteps": [
            {
              "id": "21a",
              "content": "Hot flashes/flushes: sudden heat sensation, sweating, flushing"
            },
            {
              "id": "21b",
              "content": "Most common symptom (~75% of women)"
            },
            {
              "id": "21c",
              "content": "Duration: 30 seconds to 5 minutes"
            },
            {
              "id": "21d",
              "content": "First-line: Hormone therapy (estrogen \u00b1 progestin)"
            }
          ],
          "comments": [
            "Night sweats can disrupt sleep",
            "Non-hormonal options available"
          ]
        },
        {
          "id": "wh-22",
          "stepNumber": 22,
          "title": "What are the hormone therapy options for menopause?",
          "pageRef": "p.15-16",
          "subSteps": [
            {
              "id": "22a",
              "content": "Estrogen-only: for women without uterus (hysterectomy)"
            },
            {
              "id": "22b",
              "content": "Estrogen + progestin: for women with intact uterus"
            },
            {
              "id": "22c",
              "content": "Progestin prevents endometrial hyperplasia/cancer"
            },
            {
              "id": "22d",
              "content": "Use lowest effective dose for shortest duration"
            }
          ]
        },
        {
          "id": "wh-23",
          "stepNumber": 23,
          "title": "What are the contraindications for hormone therapy?",
          "pageRef": "p.16",
          "comments": [
            "Undiagnosed abnormal vaginal bleeding",
            "History of breast cancer",
            "Estrogen-dependent neoplasia",
            "Active or history of VTE, DVT, PE",
            "Active or recent arterial thromboembolic disease",
            "Liver dysfunction or disease",
            "Known protein C, protein S, or antithrombin deficiency"
          ]
        },
        {
          "id": "wh-24",
          "stepNumber": 24,
          "title": "What are the risks of hormone therapy?",
          "pageRef": "p.16-17",
          "subSteps": [
            {
              "id": "24a",
              "content": "Increased risk: VTE, stroke, breast cancer (with progestin)"
            },
            {
              "id": "24b",
              "content": "Estrogen-only: increased endometrial cancer risk"
            },
            {
              "id": "24c",
              "content": "Risk increases with duration of use"
            },
            {
              "id": "24d",
              "content": "Higher risk if started >10 years after menopause or age >60"
            }
          ],
          "comments": [
            "Benefits may outweigh risks if started early (<60 yo or <10 years since menopause)"
          ]
        },
        {
          "id": "wh-25",
          "stepNumber": 25,
          "title": "What are the non-hormonal options for vasomotor symptoms?",
          "pageRef": "p.17-18",
          "subSteps": [
            {
              "id": "25a",
              "content": "Paroxetine 7.5 mg: only FDA-approved non-hormonal (Brisdelle)"
            },
            {
              "id": "25b",
              "content": "Off-label SSRIs/SNRIs: venlafaxine, desvenlafaxine, escitalopram"
            },
            {
              "id": "25c",
              "content": "Gabapentin 300 mg TID (off-label)"
            },
            {
              "id": "25d",
              "content": "Avoid: tamoxifen, raloxifene (worsen hot flashes)"
            }
          ],
          "comments": [
            "Less effective than hormone therapy but useful when HT contraindicated"
          ]
        },
        {
          "id": "wh-26",
          "stepNumber": 26,
          "title": "What is the genitourinary syndrome of menopause (GSM)?",
          "pageRef": "p.18",
          "subSteps": [
            {
              "id": "26a",
              "content": "Vulvovaginal atrophy: dryness, burning, irritation, dyspareunia"
            },
            {
              "id": "26b",
              "content": "Vaginal pH increases (more alkaline)"
            },
            {
              "id": "26c",
              "content": "Treatment: vaginal estrogen therapy (preferred)"
            },
            {
              "id": "26d",
              "content": "Alternative: ospemifene (oral SERM), vaginal DHEA"
            }
          ],
          "comments": [
            "Vaginal estrogen has minimal systemic absorption",
            "Vaginal moisturizers/lubricants for mild symptoms"
          ]
        },
        {
          "id": "wh-27",
          "stepNumber": 27,
          "title": "What are the vaginal estrogen therapy options?",
          "pageRef": "p.18-19",
          "subSteps": [
            {
              "id": "27a",
              "content": "Estradiol cream (Estrace): 0.5-2 g daily x2 weeks, then 1-3x/week"
            },
            {
              "id": "27b",
              "content": "Estradiol vaginal insert (Imvexxy): 4 mcg or 10 mcg daily"
            },
            {
              "id": "27c",
              "content": "Estradiol ring (Estring): 2 mg, q90 days"
            },
            {
              "id": "27d",
              "content": "Conjugated estrogen cream (Premarin): 0.5 g daily x3 weeks"
            }
          ],
          "comments": [
            "Progestin NOT needed with low-dose vaginal estrogen"
          ]
        },
        {
          "id": "wh-28",
          "stepNumber": 28,
          "title": "What is osteoporosis and its diagnostic criteria?",
          "pageRef": "p.20",
          "subSteps": [
            {
              "id": "28a",
              "content": "Skeletal disorder: compromised bone strength, increased fracture risk"
            },
            {
              "id": "28b",
              "content": "Diagnosis: T-score \u2264-2.5 (DEXA scan)"
            },
            {
              "id": "28c",
              "content": "Osteopenia: T-score -1.0 to -2.5"
            },
            {
              "id": "28d",
              "content": "Normal: T-score \u2265-1.0"
            }
          ],
          "comments": [
            "Estrogen deficiency major risk factor in women",
            "Often asymptomatic until fracture"
          ]
        },
        {
          "id": "wh-29",
          "stepNumber": 29,
          "title": "What are the risk factors for osteoporosis?",
          "pageRef": "p.20-21",
          "subSteps": [
            {
              "id": "29a",
              "content": "Non-modifiable: age, female, Caucasian/Asian, family history, small frame"
            },
            {
              "id": "29b",
              "content": "Modifiable: low calcium/vitamin D, sedentary, smoking, excess alcohol"
            },
            {
              "id": "29c",
              "content": "Medical: early menopause, hyperthyroidism, hyperparathyroidism"
            },
            {
              "id": "29d",
              "content": "Medications: glucocorticoids, anticonvulsants, PPIs, SSRIs"
            }
          ]
        },
        {
          "id": "wh-30",
          "stepNumber": 30,
          "title": "Who should be screened for osteoporosis?",
          "pageRef": "p.21",
          "comments": [
            "Women \u226565 years",
            "Postmenopausal women <65 with risk factors",
            "Men \u226570 years",
            "Adults with fracture after age 50",
            "Adults with conditions associated with low bone mass"
          ]
        },
        {
          "id": "wh-31",
          "stepNumber": 31,
          "title": "What are the calcium and vitamin D recommendations for osteoporosis prevention?",
          "pageRef": "p.21-22",
          "subSteps": [
            {
              "id": "31a",
              "content": "Calcium: 1000-1200 mg/day (diet + supplements)"
            },
            {
              "id": "31b",
              "content": "Vitamin D: 800-1000 IU/day"
            },
            {
              "id": "31c",
              "content": "Calcium carbonate: take with food (needs acid)"
            },
            {
              "id": "31d",
              "content": "Calcium citrate: can take without food"
            }
          ],
          "comments": [
            "Separate from levothyroxine, bisphosphonates, fluoroquinolones by 2-4 hours"
          ]
        },
        {
          "id": "wh-32",
          "stepNumber": 32,
          "title": "What are the bisphosphonate options for osteoporosis?",
          "pageRef": "p.22-23",
          "subSteps": [
            {
              "id": "32a",
              "content": "Alendronate: 70 mg PO weekly or 10 mg daily"
            },
            {
              "id": "32b",
              "content": "Risedronate: 35 mg PO weekly, 150 mg monthly, or 5 mg daily"
            },
            {
              "id": "32c",
              "content": "Ibandronate: 150 mg PO monthly or 3 mg IV q3 months"
            },
            {
              "id": "32d",
              "content": "Zoledronic acid: 5 mg IV annually"
            }
          ],
          "comments": [
            "First-line for most patients",
            "Reduce fracture risk 40-50%"
          ]
        },
        {
          "id": "wh-33",
          "stepNumber": 33,
          "title": "What are the administration requirements for oral bisphosphonates?",
          "pageRef": "p.22-23",
          "subSteps": [
            {
              "id": "33a",
              "content": "Take on empty stomach with 8 oz plain water"
            },
            {
              "id": "33b",
              "content": "Remain upright (sitting/standing) 30-60 minutes"
            },
            {
              "id": "33c",
              "content": "Wait 30-60 minutes before eating, drinking, or other medications"
            },
            {
              "id": "33d",
              "content": "Do not lie down for 30-60 minutes after dose"
            }
          ],
          "comments": [
            "Poor oral bioavailability (~1%)",
            "Prevents esophageal irritation"
          ]
        },
        {
          "id": "wh-34",
          "stepNumber": 34,
          "title": "What are the adverse effects of bisphosphonates?",
          "pageRef": "p.23",
          "subSteps": [
            {
              "id": "34a",
              "content": "GI: esophagitis, esophageal ulcers, abdominal pain, nausea"
            },
            {
              "id": "34b",
              "content": "Musculoskeletal pain (can be severe)"
            },
            {
              "id": "34c",
              "content": "Osteonecrosis of jaw (rare, higher with IV)"
            },
            {
              "id": "34d",
              "content": "Atypical femoral fractures (rare, with long-term use)"
            }
          ],
          "comments": [
            "Contraindicated: CrCl <30-35 mL/min, esophageal abnormalities"
          ]
        },
        {
          "id": "wh-35",
          "stepNumber": 35,
          "title": "What is denosumab (Prolia) and its dosing?",
          "pageRef": "p.23-24",
          "subSteps": [
            {
              "id": "35a",
              "content": "RANKL inhibitor: prevents osteoclast formation/function"
            },
            {
              "id": "35b",
              "content": "60 mg SubQ q6 months"
            },
            {
              "id": "35c",
              "content": "Can use in renal impairment (unlike bisphosphonates)"
            },
            {
              "id": "35d",
              "content": "Discontinuation \u2192 rapid bone loss and increased fracture risk"
            }
          ],
          "comments": [
            "Ensure adequate calcium/vitamin D",
            "Preferred if CrCl <30-35 mL/min"
          ]
        },
        {
          "id": "wh-36",
          "stepNumber": 36,
          "title": "What are the adverse effects of denosumab?",
          "pageRef": "p.24",
          "comments": [
            "Hypocalcemia (especially if CrCl <30 mL/min)",
            "Musculoskeletal pain",
            "Serious infections",
            "Dermatologic reactions",
            "Osteonecrosis of jaw (rare)",
            "Atypical femoral fractures (rare)"
          ]
        },
        {
          "id": "wh-37",
          "stepNumber": 37,
          "title": "What is raloxifene (Evista) and its use?",
          "pageRef": "p.24",
          "subSteps": [
            {
              "id": "37a",
              "content": "Selective Estrogen Receptor Modulator (SERM)"
            },
            {
              "id": "37b",
              "content": "60 mg PO daily"
            },
            {
              "id": "37c",
              "content": "Reduces vertebral fractures (NOT hip)"
            },
            {
              "id": "37d",
              "content": "Also reduces breast cancer risk"
            }
          ],
          "comments": [
            "Increased VTE risk",
            "Worsens hot flashes",
            "Less effective than bisphosphonates"
          ]
        },
        {
          "id": "wh-38",
          "stepNumber": 38,
          "title": "What is teriparatide (Forteo) and its characteristics?",
          "pageRef": "p.24-25",
          "subSteps": [
            {
              "id": "38a",
              "content": "Recombinant PTH analog: stimulates bone formation"
            },
            {
              "id": "38b",
              "content": "20 mcg SubQ daily"
            },
            {
              "id": "38c",
              "content": "Maximum duration: 2 years lifetime"
            },
            {
              "id": "38d",
              "content": "For severe osteoporosis or high fracture risk"
            }
          ],
          "comments": [
            "BBW: osteosarcoma in animal studies",
            "Expensive",
            "Requires refrigeration"
          ]
        },
        {
          "id": "wh-39",
          "stepNumber": 39,
          "title": "What is romosozumab (Evenity)?",
          "pageRef": "p.25",
          "subSteps": [
            {
              "id": "39a",
              "content": "Sclerostin inhibitor: increases bone formation, decreases resorption"
            },
            {
              "id": "39b",
              "content": "210 mg SubQ monthly x12 months"
            },
            {
              "id": "39c",
              "content": "For postmenopausal women at high fracture risk"
            },
            {
              "id": "39d",
              "content": "BBW: increased cardiovascular risk (MI, stroke)"
            }
          ],
          "comments": [
            "Contraindicated: MI or stroke within prior year",
            "Followed by antiresorptive after 12 months"
          ]
        },
        {
          "id": "wh-40",
          "stepNumber": 40,
          "title": "What is the duration of osteoporosis treatment?",
          "pageRef": "p.25",
          "subSteps": [
            {
              "id": "40a",
              "content": "Bisphosphonates: 3-5 years, then reassess"
            },
            {
              "id": "40b",
              "content": "Drug holiday possible if low risk after 3-5 years"
            },
            {
              "id": "40c",
              "content": "Continue if: T-score <-2.5, history of fracture, high risk"
            },
            {
              "id": "40d",
              "content": "Denosumab: no drug holiday (rapid bone loss on discontinuation)"
            }
          ]
        },
        {
          "id": "wh-41",
          "stepNumber": 41,
          "title": "How do you monitor osteoporosis treatment?",
          "pageRef": "p.25-26",
          "subSteps": [
            {
              "id": "41a",
              "content": "DEXA scan: 1-2 years after initiation, then q2 years"
            },
            {
              "id": "41b",
              "content": "Serum calcium, vitamin D levels"
            },
            {
              "id": "41c",
              "content": "Bone turnover markers (optional): CTX, P1NP"
            },
            {
              "id": "41d",
              "content": "Expect BMD increase 1-3% per year"
            }
          ],
          "comments": [
            "Stable BMD = treatment success",
            "Assess fracture occurrence"
          ]
        },
        {
          "id": "wh-42",
          "stepNumber": 42,
          "title": "What are typical use failure rates for contraceptive methods?",
          "pageRef": "p.1",
          "subSteps": [
            {
              "id": "42a",
              "content": "COC/patch/ring: 7%"
            },
            {
              "id": "42b",
              "content": "Drospirenone-only: 4%"
            },
            {
              "id": "42c",
              "content": "Depo-medroxyprogesterone: 4%"
            },
            {
              "id": "42d",
              "content": "Copper IUD/Levonorgestrel IUD/Implant: <1%"
            }
          ]
        },
        {
          "id": "wh-43",
          "stepNumber": 43,
          "title": "When should hormone therapy be avoided postpartum?",
          "pageRef": "p.9",
          "subSteps": [
            {
              "id": "43a",
              "content": "Breastfeeding: avoid estrogen first 21 days postpartum"
            },
            {
              "id": "43b",
              "content": "Breastfeeding with VTE risk: avoid estrogen 42 days; without risk 30 days"
            },
            {
              "id": "43c",
              "content": "Not breastfeeding with VTE risk: avoid estrogen 42 days"
            },
            {
              "id": "43d",
              "content": "Not breastfeeding without VTE risk: avoid 21 days"
            }
          ],
          "comments": [
            "After 42 days: no restrictions"
          ]
        },
        {
          "id": "wh-44",
          "stepNumber": 44,
          "title": "What are the special considerations for CHC and thromboembolism?",
          "pageRef": "p.8-9",
          "subSteps": [
            {
              "id": "44a",
              "content": "Estrogens increase VTE risk 3X vs nonusers"
            },
            {
              "id": "44b",
              "content": "3rd/4th generation progestins: slightly higher VTE risk"
            },
            {
              "id": "44c",
              "content": "Transdermal/vaginal: increased risk (continuous/higher estrogen)"
            },
            {
              "id": "44d",
              "content": "Progestin-only: no significant increase in venous/arterial events"
            }
          ]
        },
        {
          "id": "wh-45",
          "stepNumber": 45,
          "title": "What are key patient counseling points for vaginal ring use?",
          "pageRef": "p.7",
          "subSteps": [
            {
              "id": "45a",
              "content": "If displaced <3 hours (NuvaRing) or <2 hours (Annovera): reinsert, no backup"
            },
            {
              "id": "45b",
              "content": "If displaced >3 hours (NuvaRing) or >2 hours (Annovera): reinsert, backup x7 days"
            },
            {
              "id": "45c",
              "content": "NuvaRing: store in fridge if not using promptly; okay with tampons"
            },
            {
              "id": "45d",
              "content": "Annovera: no refrigeration; avoid tampons; wash and store when removed"
            }
          ]
        }
      ]
    },
    {
      "id": "infectious-diseases-1",
      "name": "Infectious Diseases Part 1",
      "shortName": "ID Part 1",
      "totalSteps": 40,
      "steps": [
        {
          "id": "id1-1",
          "stepNumber": 1,
          "title": "What are the PK/PD targets for different antibiotic classes?",
          "pageRef": "p.3",
          "subSteps": [
            {
              "id": "1a",
              "content": "T>MIC (Time above MIC): Beta-lactams, macrolides, oxazolidinones"
            },
            {
              "id": "1b",
              "content": "AUC/MIC: Vancomycin, fluoroquinolones, tetracyclines"
            },
            {
              "id": "1c",
              "content": "Cmax/MIC: Aminoglycosides"
            }
          ],
          "comments": [
            "Optimize T>MIC: extended/continuous infusions",
            "Optimize AUC/MIC: daily dose",
            "Optimize Cmax/MIC: high dose, extended interval"
          ]
        },
        {
          "id": "id1-2",
          "stepNumber": 2,
          "title": "What are the major mechanisms of beta-lactam resistance?",
          "pageRef": "p.11",
          "comments": [
            "Beta-lactamases (most common in Gram-negatives)",
            "PBP alterations (e.g., MRSA with PBP2A)",
            "Efflux pumps",
            "Outer membrane porin down-regulation"
          ]
        },
        {
          "id": "id1-3",
          "stepNumber": 3,
          "title": "What is the mechanism of action of beta-lactam antibiotics?",
          "pageRef": "p.11-12",
          "subSteps": [
            {
              "id": "3a",
              "content": "Inhibit final step of cell wall synthesis"
            },
            {
              "id": "3b",
              "content": "Block cross-linking of peptidoglycan by binding to PBPs"
            },
            {
              "id": "3c",
              "content": "Bactericidal"
            },
            {
              "id": "3d",
              "content": "Time-dependent killing (optimize T>MIC)"
            }
          ]
        },
        {
          "id": "id1-4",
          "stepNumber": 4,
          "title": "What is the spectrum of activity for penicillin?",
          "pageRef": "p.12",
          "comments": [
            "Streptococci: S. pyogenes, S. viridans, S. pneumoniae",
            "Enterococcus faecalis",
            "Treponema pallidum (syphilis - DOC)",
            "Mouth anaerobes (variable)"
          ]
        },
        {
          "id": "id1-5",
          "stepNumber": 5,
          "title": "What are the HELPS bugs covered by aminopenicillins?",
          "pageRef": "p.14",
          "subSteps": [
            {
              "id": "5a",
              "content": "H - H. influenzae"
            },
            {
              "id": "5b",
              "content": "E - E. faecalis"
            },
            {
              "id": "5c",
              "content": "L - L. monocytogenes"
            },
            {
              "id": "5d",
              "content": "P - P. mirabilis"
            },
            {
              "id": "5e",
              "content": "S - Salmonella and Shigella"
            },
            {
              "id": "5f",
              "content": "Also: penicillin-susceptible streptococci"
            }
          ],
          "comments": [
            "Ampicillin (IV), Amoxicillin (PO)"
          ]
        },
        {
          "id": "id1-6",
          "stepNumber": 6,
          "title": "What are the penicillin/beta-lactamase inhibitor combinations?",
          "pageRef": "p.14-15",
          "subSteps": [
            {
              "id": "6a",
              "content": "Amoxicillin/Clavulanic Acid (Augmentin) - PO"
            },
            {
              "id": "6b",
              "content": "Ampicillin/Sulbactam (Unasyn) - IV"
            },
            {
              "id": "6c",
              "content": "Piperacillin/Tazobactam (Zosyn) - IV"
            }
          ],
          "comments": [
            "BLI adds: Greater Gram(-) and anaerobic activity, MSSA coverage"
          ]
        },
        {
          "id": "id1-7",
          "stepNumber": 7,
          "title": "What is piperacillin/tazobactam used for?",
          "pageRef": "p.14-15",
          "comments": [
            "Empiric broad-spectrum therapy for nosocomial infections",
            "Covers: MSSA, Streptococci, Enterococci, P. aeruginosa, Enterobacteriaceae, anaerobes",
            "Note: Tazobactam offers NO advantage for P. aeruginosa (piperacillin alone active)"
          ]
        },
        {
          "id": "id1-8",
          "stepNumber": 8,
          "title": "What are the major adverse effects of penicillins?",
          "pageRef": "p.15",
          "subSteps": [
            {
              "id": "8a",
              "content": "Hypersensitivity reactions (most common): rash, anaphylaxis"
            },
            {
              "id": "8b",
              "content": "GI upset: nausea, vomiting, diarrhea (especially Augmentin)"
            },
            {
              "id": "8c",
              "content": "Seizures: with high doses or renal impairment"
            },
            {
              "id": "8d",
              "content": "Drug fever, eosinophilia"
            }
          ],
          "comments": [
            "Cross-reactivity between penicillins and cephalosporins: ~1-2%"
          ]
        },
        {
          "id": "id1-9",
          "stepNumber": 9,
          "title": "What are the first-generation cephalosporins and their spectrum?",
          "pageRef": "p.16",
          "subSteps": [
            {
              "id": "9a",
              "content": "Agents: Cefazolin (IV), Cephalexin (PO)"
            },
            {
              "id": "9b",
              "content": "Excellent Gram(+): MSSA, Streptococci"
            },
            {
              "id": "9c",
              "content": "Moderate Gram(-): E. coli, K. pneumoniae, P. mirabilis"
            },
            {
              "id": "9d",
              "content": "Poor: Enterococcus, P. aeruginosa, anaerobes"
            }
          ],
          "comments": [
            "Use: Skin infections (MSSA), surgical prophylaxis"
          ]
        },
        {
          "id": "id1-10",
          "stepNumber": 10,
          "title": "What are the third-generation cephalosporins and their spectrum?",
          "pageRef": "p.16-17",
          "subSteps": [
            {
              "id": "10a",
              "content": "Ceftriaxone, Cefotaxime, Ceftazidime, Cefpodoxime"
            },
            {
              "id": "10b",
              "content": "Enhanced Gram(-): Enterobacteriaceae"
            },
            {
              "id": "10c",
              "content": "Ceftazidime: adds P. aeruginosa"
            },
            {
              "id": "10d",
              "content": "Decreased MSSA activity vs 1st gen"
            }
          ],
          "comments": [
            "Ceftriaxone: long half-life (24h dosing), high protein binding",
            "Use: Meningitis, CAP, gonorrhea"
          ]
        },
        {
          "id": "id1-11",
          "stepNumber": 11,
          "title": "What are the fifth-generation cephalosporins?",
          "pageRef": "p.17",
          "subSteps": [
            {
              "id": "11a",
              "content": "Ceftaroline (Teflaro), Ceftobiprole"
            },
            {
              "id": "11b",
              "content": "Activity against MRSA (unique among beta-lactams)"
            },
            {
              "id": "11c",
              "content": "Also covers: Streptococci, Enterobacteriaceae"
            },
            {
              "id": "11d",
              "content": "NO activity: Pseudomonas, Enterococcus"
            }
          ],
          "comments": [
            "Use: Skin infections with MRSA, CAP"
          ]
        },
        {
          "id": "id1-12",
          "stepNumber": 12,
          "title": "What is cefepime and its spectrum?",
          "pageRef": "p.17",
          "subSteps": [
            {
              "id": "12a",
              "content": "Fourth-generation cephalosporin"
            },
            {
              "id": "12b",
              "content": "Broad spectrum: Gram(+) and Gram(-)"
            },
            {
              "id": "12c",
              "content": "Covers: MSSA, Streptococci, Enterobacteriaceae, P. aeruginosa"
            },
            {
              "id": "12d",
              "content": "Does NOT cover: MRSA, Enterococcus, anaerobes"
            }
          ],
          "comments": [
            "Common empiric agent for nosocomial infections",
            "Good CNS penetration"
          ]
        },
        {
          "id": "id1-13",
          "stepNumber": 13,
          "title": "What are the carbapenem options and their spectrum?",
          "pageRef": "p.18",
          "subSteps": [
            {
              "id": "13a",
              "content": "Imipenem/Cilastatin, Meropenem, Ertapenem, Doripenem"
            },
            {
              "id": "13b",
              "content": "Broadest spectrum beta-lactams"
            },
            {
              "id": "13c",
              "content": "Covers: MSSA, Streptococci, Enterobacteriaceae, P. aeruginosa (except ertapenem), anaerobes"
            },
            {
              "id": "13d",
              "content": "Does NOT cover: MRSA, Enterococcus faecium, atypicals"
            }
          ],
          "comments": [
            "Ertapenem: NO Pseudomonas or Enterococcus coverage",
            "Reserved for resistant infections"
          ]
        },
        {
          "id": "id1-14",
          "stepNumber": 14,
          "title": "What is aztreonam and when is it used?",
          "pageRef": "p.19",
          "subSteps": [
            {
              "id": "14a",
              "content": "Monobactam (only one available)"
            },
            {
              "id": "14b",
              "content": "Spectrum: Gram(-) ONLY (Enterobacteriaceae, P. aeruginosa)"
            },
            {
              "id": "14c",
              "content": "NO Gram(+) or anaerobic activity"
            },
            {
              "id": "14d",
              "content": "Safe in penicillin/cephalosporin allergy (different ring structure)"
            }
          ],
          "comments": [
            "Use: Beta-lactam allergic patients needing Gram(-) coverage"
          ]
        },
        {
          "id": "id1-15",
          "stepNumber": 15,
          "title": "What are Extended-Spectrum Beta-Lactamases (ESBLs)?",
          "pageRef": "p.19-20",
          "subSteps": [
            {
              "id": "15a",
              "content": "Enzymes that hydrolyze penicillins and cephalosporins"
            },
            {
              "id": "15b",
              "content": "Common in: E. coli, K. pneumoniae"
            },
            {
              "id": "15c",
              "content": "Treatment: Carbapenems (drug of choice)"
            },
            {
              "id": "15d",
              "content": "Alternative: Piperacillin/tazobactam (if susceptible and not severe)"
            }
          ],
          "comments": [
            "Resistance to: penicillins, cephalosporins, aztreonam",
            "Susceptible to: carbapenems, beta-lactamase inhibitors"
          ]
        },
        {
          "id": "id1-16",
          "stepNumber": 16,
          "title": "What are Carbapenem-Resistant Enterobacteriaceae (CRE)?",
          "pageRef": "p.20",
          "subSteps": [
            {
              "id": "16a",
              "content": "Produce carbapenemases (KPC most common in US)"
            },
            {
              "id": "16b",
              "content": "Resistant to: ALL beta-lactams"
            },
            {
              "id": "16c",
              "content": "Treatment: Polymyxins (colistin, polymyxin B), tigecycline, newer agents"
            },
            {
              "id": "16d",
              "content": "Newer agents: Meropenem/vaborbactam, imipenem/relebactam, ceftazidime/avibactam"
            }
          ],
          "comments": [
            "Urgent threat - high mortality",
            "Often require combination therapy"
          ]
        },
        {
          "id": "id1-17",
          "stepNumber": 17,
          "title": "What is the only treatment indication for asymptomatic bacteriuria?",
          "pageRef": "p.10",
          "comments": [
            "Pregnancy",
            "Undergoing urological procedure (TURP)",
            "Do NOT treat otherwise - leads to increased resistance, C. diff, adverse events, INCREASES recurrent UTIs",
            "#1 cause of inappropriate antimicrobial usage in hospitals"
          ]
        },
        {
          "id": "id1-18",
          "stepNumber": 18,
          "title": "What antibiotics have highest C. difficile risk?",
          "pageRef": "p.8",
          "subSteps": [
            {
              "id": "18a",
              "content": "3rd gen cephalosporins: OR 3.20"
            },
            {
              "id": "18b",
              "content": "Clindamycin: OR 2.86"
            },
            {
              "id": "18c",
              "content": "2nd gen cephalosporins: OR 2.23"
            },
            {
              "id": "18d",
              "content": "Cefepime: OR 2.14"
            },
            {
              "id": "18e",
              "content": "Carbapenems: OR 1.84"
            }
          ]
        },
        {
          "id": "id1-19",
          "stepNumber": 19,
          "title": "What are the cephalosporin generations and their uses?",
          "pageRef": "p.16-17",
          "subSteps": [
            {
              "id": "19a",
              "content": "1st gen: Excellent Gram(+), moderate Gram(-); Use: Skin infections, surgical prophylaxis"
            },
            {
              "id": "19b",
              "content": "2nd gen: Improved Gram(-); Use: Respiratory, intra-abdominal"
            },
            {
              "id": "19c",
              "content": "3rd gen: Enhanced Gram(-), some Pseudomonas (ceftazidime); Use: Meningitis, CAP"
            },
            {
              "id": "19d",
              "content": "4th gen (Cefepime): Broad Gram(+) and Gram(-), Pseudomonas"
            },
            {
              "id": "19e",
              "content": "5th gen (Ceftaroline): Adds MRSA coverage"
            }
          ]
        },
        {
          "id": "id1-20",
          "stepNumber": 20,
          "title": "What is the difference between empiric and definitive therapy?",
          "pageRef": "p.2",
          "subSteps": [
            {
              "id": "20a",
              "content": "Empiric: Therapy before causative organism known; based on common pathogens"
            },
            {
              "id": "20b",
              "content": "Definitive: Once cultures and sensitivities available; targeted therapy"
            },
            {
              "id": "20c",
              "content": "Always try to de-escalate from empiric to definitive"
            }
          ]
        },
        {
          "id": "id1-21",
          "stepNumber": 21,
          "title": "What are the goals of antimicrobial stewardship?",
          "pageRef": "p.4",
          "comments": [
            "Optimize clinical outcomes (appropriate selection, dose, route, duration)",
            "Minimize toxicity",
            "Minimize emergence of resistant pathogens (MRSA, VRE, MDR organisms)",
            "Minimize superinfections (C. difficile, Candida)",
            "Reduce antimicrobial expenditure"
          ]
        },
        {
          "id": "id1-22",
          "stepNumber": 22,
          "title": "What is the cost and impact of antimicrobial resistance?",
          "pageRef": "p.6",
          "subSteps": [
            {
              "id": "22a",
              "content": "Total annual cost: ~$30 billion"
            },
            {
              "id": "22b",
              "content": "MRSA bacteremia: 1.9x mortality, +2.2 days, +$6,916"
            },
            {
              "id": "22c",
              "content": "VRE: 2.1x mortality, +6.2 days, +$12,766"
            },
            {
              "id": "22d",
              "content": "Resistant Pseudomonas: 3.0x mortality, +5.7 days"
            },
            {
              "id": "22e",
              "content": "Resistant Enterobacter: 5.0x mortality, +9 days, +$29,379"
            }
          ]
        },
        {
          "id": "id1-23",
          "stepNumber": 23,
          "title": "What are penicillinase-resistant penicillins and their use?",
          "pageRef": "p.13",
          "subSteps": [
            {
              "id": "23a",
              "content": "Agents: Nafcillin, Oxacillin, Dicloxacillin"
            },
            {
              "id": "23b",
              "content": "Designed to overcome penicillinase"
            },
            {
              "id": "23c",
              "content": "Spectrum: MSSA, Streptococci"
            },
            {
              "id": "23d",
              "content": "Does NOT cover: MRSA (all beta-lactams inactive), Gram(-), Enterococcus, anaerobes"
            }
          ],
          "comments": [
            "Methicillin not clinically used but important for nomenclature (MSSA/MRSA)"
          ]
        },
        {
          "id": "id1-24",
          "stepNumber": 24,
          "title": "How does MRSA develop resistance to beta-lactams?",
          "pageRef": "p.13-14",
          "subSteps": [
            {
              "id": "24a",
              "content": "PBP2 \u2192 PBP2A alteration"
            },
            {
              "id": "24b",
              "content": "PBP2A has decreased affinity for all beta-lactams"
            },
            {
              "id": "24c",
              "content": "Can carry out transpeptidation even with beta-lactams present"
            },
            {
              "id": "24d",
              "content": "Confers resistance to ALL beta-lactams (except ceftaroline)"
            }
          ]
        },
        {
          "id": "id1-25",
          "stepNumber": 25,
          "title": "What organisms are covered by piperacillin/tazobactam?",
          "pageRef": "p.14-15",
          "comments": [
            "Gram(+): MSSA, Streptococci, E. faecalis",
            "Gram(-): Enterobacteriaceae, P. aeruginosa",
            "Anaerobes: B. fragilis",
            "Does NOT cover: MRSA, E. faecium, atypicals"
          ]
        },
        {
          "id": "id1-26",
          "stepNumber": 26,
          "title": "What is benzathine penicillin and its use?",
          "pageRef": "p.12",
          "subSteps": [
            {
              "id": "26a",
              "content": "Long-acting depot preparation"
            },
            {
              "id": "26b",
              "content": "Must be given IM"
            },
            {
              "id": "26c",
              "content": "Slow steady release \u2192 low-level concentration for long period"
            },
            {
              "id": "26d",
              "content": "Use: Syphilis (all stages)"
            }
          ]
        },
        {
          "id": "id1-27",
          "stepNumber": 27,
          "title": "What are the adverse effects of cephalosporins?",
          "pageRef": "p.17-18",
          "subSteps": [
            {
              "id": "27a",
              "content": "Hypersensitivity: Cross-reactivity with penicillins ~1-2%"
            },
            {
              "id": "27b",
              "content": "GI upset: nausea, diarrhea"
            },
            {
              "id": "27c",
              "content": "Ceftriaxone: biliary sludging, do NOT use in neonates (kernicterus)"
            },
            {
              "id": "27d",
              "content": "Disulfiram-like reaction: cefotetan with alcohol"
            }
          ]
        },
        {
          "id": "id1-28",
          "stepNumber": 28,
          "title": "What are the adverse effects of carbapenems?",
          "pageRef": "p.18-19",
          "subSteps": [
            {
              "id": "28a",
              "content": "Seizures: especially imipenem (highest risk), with high doses or renal impairment"
            },
            {
              "id": "28b",
              "content": "GI upset: nausea, vomiting, diarrhea"
            },
            {
              "id": "28c",
              "content": "Hypersensitivity: cross-reactivity with penicillins (~1%)"
            }
          ],
          "comments": [
            "Meropenem has lower seizure risk than imipenem"
          ]
        },
        {
          "id": "id1-29",
          "stepNumber": 29,
          "title": "What is the spectrum and use of ertapenem?",
          "pageRef": "p.18",
          "subSteps": [
            {
              "id": "29a",
              "content": "Covers: MSSA, Streptococci, Enterobacteriaceae, anaerobes"
            },
            {
              "id": "29b",
              "content": "Does NOT cover: Pseudomonas, Enterococcus, MRSA"
            },
            {
              "id": "29c",
              "content": "Once-daily dosing"
            },
            {
              "id": "29d",
              "content": "Use: Community-acquired intra-abdominal infections, complicated UTI"
            }
          ]
        },
        {
          "id": "id1-30",
          "stepNumber": 30,
          "title": "What are the newer beta-lactam/beta-lactamase inhibitor combinations?",
          "pageRef": "p.20",
          "subSteps": [
            {
              "id": "30a",
              "content": "Ceftazidime/Avibactam: covers CRE, ESBL, AmpC, Pseudomonas"
            },
            {
              "id": "30b",
              "content": "Meropenem/Vaborbactam: covers CRE (KPC), Enterobacteriaceae"
            },
            {
              "id": "30c",
              "content": "Imipenem/Relebactam: covers Pseudomonas, some CRE"
            },
            {
              "id": "30d",
              "content": "Ceftolozane/Tazobactam: enhanced Pseudomonas coverage"
            }
          ]
        },
        {
          "id": "id1-31",
          "stepNumber": 31,
          "title": "What is the clinical use of first-generation cephalosporins?",
          "pageRef": "p.16",
          "comments": [
            "Skin and soft tissue infections (MSSA)",
            "Surgical prophylaxis (cefazolin)",
            "Alternative to anti-staphylococcal penicillins",
            "Streptococcal pharyngitis"
          ]
        },
        {
          "id": "id1-32",
          "stepNumber": 32,
          "title": "What are the key characteristics of ceftriaxone?",
          "pageRef": "p.17",
          "subSteps": [
            {
              "id": "32a",
              "content": "Long half-life: allows once-daily dosing"
            },
            {
              "id": "32b",
              "content": "High protein binding"
            },
            {
              "id": "32c",
              "content": "Biliary excretion (can cause sludging)"
            },
            {
              "id": "32d",
              "content": "Do NOT use in neonates (displaces bilirubin \u2192 kernicterus)"
            }
          ],
          "comments": [
            "Use: Meningitis, gonorrhea, CAP, Lyme disease"
          ]
        },
        {
          "id": "id1-33",
          "stepNumber": 33,
          "title": "What defines susceptible, intermediate, and resistant?",
          "pageRef": "p.3",
          "subSteps": [
            {
              "id": "33a",
              "content": "Susceptible: PK/PD targets achievable, expect clinical success with common doses"
            },
            {
              "id": "33b",
              "content": "Intermediate: MICs elevated, might see success with dose optimization"
            },
            {
              "id": "33c",
              "content": "Resistant: PK/PD targets not obtainable, would NOT expect clinical success"
            }
          ]
        },
        {
          "id": "id1-34",
          "stepNumber": 34,
          "title": "What are the steps for selecting empiric antimicrobials?",
          "pageRef": "p.4",
          "subSteps": [
            {
              "id": "34a",
              "content": "1. Have a working diagnosis"
            },
            {
              "id": "34b",
              "content": "2. Know common pathogens for expected infection"
            },
            {
              "id": "34c",
              "content": "3. Consider patient-specific factors (allergies, previous abx, organ disease, history of resistance)"
            },
            {
              "id": "34d",
              "content": "4. Obtain cultures"
            },
            {
              "id": "34e",
              "content": "5. Start empiric therapy"
            },
            {
              "id": "34f",
              "content": "6. Await diagnostics"
            },
            {
              "id": "34g",
              "content": "7. Streamline/de-escalate based on cultures"
            }
          ]
        },
        {
          "id": "id1-35",
          "stepNumber": 35,
          "title": "What is the relationship between antibiotic exposure and resistance?",
          "pageRef": "p.5-6",
          "subSteps": [
            {
              "id": "35a",
              "content": "Previous antibiotic exposure in last 90 days increases resistance risk"
            },
            {
              "id": "35b",
              "content": "More exposures \u2192 higher odds ratio (0 exposures: OR 1.0; \u22653: OR 2.93)"
            },
            {
              "id": "35c",
              "content": "Each additional day of antibiotics: OR 1.04 for resistance"
            },
            {
              "id": "35d",
              "content": "Carbapenem use correlates with CRE isolates"
            }
          ]
        },
        {
          "id": "id1-36",
          "stepNumber": 36,
          "title": "What distinguishes bactericidal from bacteriostatic antibiotics?",
          "pageRef": "p.2",
          "subSteps": [
            {
              "id": "36a",
              "content": "Bactericidal: Number of bacteria decrease when exposed (kill bacteria)"
            },
            {
              "id": "36b",
              "content": "Bacteriostatic: Number stays the same (inhibit growth, host kills)"
            },
            {
              "id": "36c",
              "content": "Bactericidal: Beta-lactams, fluoroquinolones, aminoglycosides, metronidazole"
            },
            {
              "id": "36d",
              "content": "Bacteriostatic: Tetracyclines, macrolides, linezolid, clindamycin"
            }
          ]
        },
        {
          "id": "id1-37",
          "stepNumber": 37,
          "title": "When are enterococcal infections treated with synergistic combinations?",
          "pageRef": "p.14",
          "subSteps": [
            {
              "id": "37a",
              "content": "Ampicillin ALONE only bacteriostatic against E. faecalis"
            },
            {
              "id": "37b",
              "content": "For life-threatening infections: endocarditis, osteomyelitis"
            },
            {
              "id": "37c",
              "content": "Use ampicillin + (ceftriaxone OR gentamicin) for synergy"
            },
            {
              "id": "37d",
              "content": "Achieves bactericidal activity"
            }
          ]
        },
        {
          "id": "id1-38",
          "stepNumber": 38,
          "title": "What percentage of antibiotic use is inappropriate in different settings?",
          "pageRef": "p.8",
          "comments": [
            "Outpatient: 30% inappropriate",
            "Acute care (hospital): 50% inappropriate",
            "Long-term care: 70% inappropriate",
            "Asymptomatic bacteriuria: #1 cause of inappropriate hospital use"
          ]
        },
        {
          "id": "id1-39",
          "stepNumber": 39,
          "title": "What are AmpC beta-lactamases?",
          "pageRef": "p.19-20",
          "subSteps": [
            {
              "id": "39a",
              "content": "Chromosomally-encoded (Enterobacter, Citrobacter, Serratia, Morganella)"
            },
            {
              "id": "39b",
              "content": "Confer resistance to: 1st/2nd/3rd gen cephalosporins, penicillins"
            },
            {
              "id": "39c",
              "content": "Susceptible to: Cefepime, carbapenems"
            },
            {
              "id": "39d",
              "content": "NOT inhibited by traditional beta-lactamase inhibitors"
            }
          ]
        },
        {
          "id": "id1-40",
          "stepNumber": 40,
          "title": "What are the major clinically important bacteria to know?",
          "pageRef": "p.1",
          "subSteps": [
            {
              "id": "40a",
              "content": "Gram(+): Streptococcus spp., S. aureus, Enterococcus spp."
            },
            {
              "id": "40b",
              "content": "Enteric Gram(-): E. coli, K. pneumoniae, Proteus spp."
            },
            {
              "id": "40c",
              "content": "Nosocomial Gram(-): P. aeruginosa, A. baumannii, Enterobacter, Citrobacter, Serratia"
            },
            {
              "id": "40d",
              "content": "Others: Anaerobes, respiratory organisms, C. difficile"
            }
          ]
        }
      ]
    },
    {
      "id": "infectious-diseases-2",
      "name": "Infectious Diseases Part 2",
      "shortName": "ID Part 2",
      "totalSteps": 35,
      "steps": [
        {
          "id": "id2-1",
          "stepNumber": 1,
          "title": "What is vancomycin and its mechanism of action?",
          "pageRef": "p.2-3",
          "subSteps": [
            {
              "id": "1a",
              "content": "Inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala"
            },
            {
              "id": "1b",
              "content": "Bactericidal against most Gram-positive organisms"
            },
            {
              "id": "1c",
              "content": "Excellent activity: MRSA, MSSA, Streptococcus, Enterococcus"
            },
            {
              "id": "1d",
              "content": "NO activity: Gram-negative organisms"
            }
          ],
          "comments": [
            "Increasing MICs in MRSA ('MIC creep')"
          ]
        },
        {
          "id": "id2-2",
          "stepNumber": 2,
          "title": "What is the dosing and monitoring for vancomycin?",
          "pageRef": "p.3",
          "subSteps": [
            {
              "id": "2a",
              "content": "Standard: 15-20 mg/kg IV q8-12h"
            },
            {
              "id": "2b",
              "content": "Loading dose: 25-30 mg/kg for serious infections"
            },
            {
              "id": "2c",
              "content": "Target trough: 15-20 mcg/mL for serious infections"
            },
            {
              "id": "2d",
              "content": "AUC/MIC targeting preferred: target AUC 400-600"
            }
          ],
          "comments": [
            "TDM recommended for serious infections",
            "Adjust dose in renal impairment"
          ]
        },
        {
          "id": "id2-3",
          "stepNumber": 3,
          "title": "What are the adverse effects of vancomycin?",
          "pageRef": "p.3",
          "subSteps": [
            {
              "id": "3a",
              "content": "Nephrotoxicity: dose-dependent, risk \u2191 with trough >20 mcg/mL"
            },
            {
              "id": "3b",
              "content": "Ototoxicity: rare, associated with high troughs"
            },
            {
              "id": "3c",
              "content": "Red Man Syndrome: histamine-mediated infusion reaction"
            },
            {
              "id": "3d",
              "content": "Thrombophlebitis: common with peripheral IV"
            }
          ],
          "comments": [
            "Red Man prevention: slow infusion (\u22651 hour per 500 mg), antihistamines"
          ]
        },
        {
          "id": "id2-4",
          "stepNumber": 4,
          "title": "What is daptomycin and its characteristics?",
          "pageRef": "p.3-4",
          "subSteps": [
            {
              "id": "4a",
              "content": "Lipopeptide that depolarizes bacterial cell membrane"
            },
            {
              "id": "4b",
              "content": "Concentration-dependent bactericidal activity"
            },
            {
              "id": "4c",
              "content": "Spectrum: Gram-positive only (MRSA, MSSA, VRE, Strep)"
            },
            {
              "id": "4d",
              "content": "NOT effective for pneumonia (inactivated by surfactant)"
            }
          ]
        },
        {
          "id": "id2-5",
          "stepNumber": 5,
          "title": "What is the dosing and monitoring for daptomycin?",
          "pageRef": "p.4",
          "subSteps": [
            {
              "id": "5a",
              "content": "ABSSSI: 4 mg/kg IV q24h"
            },
            {
              "id": "5b",
              "content": "Bacteremia/endocarditis: 6-8 mg/kg q24h (up to 10-12 mg/kg)"
            },
            {
              "id": "5c",
              "content": "Adjust for CrCl <30 mL/min: dose q48h"
            },
            {
              "id": "5d",
              "content": "Monitor CPK weekly"
            }
          ],
          "comments": [
            "D/C if CPK >1000 U/L with symptoms or >2000 U/L",
            "Hold statins during therapy"
          ]
        },
        {
          "id": "id2-6",
          "stepNumber": 6,
          "title": "What is linezolid and its characteristics?",
          "pageRef": "p.4-5",
          "subSteps": [
            {
              "id": "6a",
              "content": "Oxazolidinone: inhibits protein synthesis (50S ribosomal subunit)"
            },
            {
              "id": "6b",
              "content": "Spectrum: MRSA, VRE, Strep"
            },
            {
              "id": "6c",
              "content": "Dosing: 600 mg PO/IV q12h"
            },
            {
              "id": "6d",
              "content": "100% oral bioavailability, excellent tissue penetration"
            }
          ],
          "comments": [
            "Active against VRE",
            "Good CNS penetration"
          ]
        },
        {
          "id": "id2-7",
          "stepNumber": 7,
          "title": "What are the adverse effects of linezolid?",
          "pageRef": "p.5",
          "subSteps": [
            {
              "id": "7a",
              "content": "Myelosuppression: thrombocytopenia, anemia (monitor CBC weekly if >2 weeks)"
            },
            {
              "id": "7b",
              "content": "Peripheral/optic neuropathy: with prolonged use >28 days"
            },
            {
              "id": "7c",
              "content": "Lactic acidosis: rare"
            },
            {
              "id": "7d",
              "content": "Serotonin syndrome: with SSRIs, SNRIs, MAOIs"
            }
          ],
          "comments": [
            "MAO inhibitor activity - avoid tyramine-rich foods"
          ]
        },
        {
          "id": "id2-8",
          "stepNumber": 8,
          "title": "What are treatment options for VRE?",
          "pageRef": "p.5",
          "comments": [
            "Linezolid: first-line for VRE infections",
            "Daptomycin: 8-12 mg/kg q24h (higher doses for endocarditis)",
            "Quinupristin/Dalfopristin: VRE faecium ONLY (not faecalis)",
            "Tigecycline: reserve for limited options"
          ]
        },
        {
          "id": "id2-9",
          "stepNumber": 9,
          "title": "What are the fluoroquinolones and their spectrum?",
          "pageRef": "p.6-7",
          "subSteps": [
            {
              "id": "9a",
              "content": "MOA: Inhibit DNA gyrase and topoisomerase IV"
            },
            {
              "id": "9b",
              "content": "Concentration-dependent bactericidal activity"
            },
            {
              "id": "9c",
              "content": "PK/PD target: AUC/MIC >30-40 (Gram-neg), >100 (Strep)"
            },
            {
              "id": "9d",
              "content": "Broad coverage: Gram(+), Gram(-), atypicals"
            }
          ]
        },
        {
          "id": "id2-10",
          "stepNumber": 10,
          "title": "What are the individual fluoroquinolone agents and their uses?",
          "pageRef": "p.7",
          "subSteps": [
            {
              "id": "10a",
              "content": "Levofloxacin: CAP, UTI, ABSSSI, prostatitis (500-750 mg q24h)"
            },
            {
              "id": "10b",
              "content": "Moxifloxacin: CAP, enhanced Gram(+) and anaerobic (400 mg q24h, NOT for UTI)"
            },
            {
              "id": "10c",
              "content": "Ciprofloxacin: Excellent Gram(-) including Pseudomonas, UTI (250-750 mg q12h)"
            },
            {
              "id": "10d",
              "content": "Delafloxacin: ABSSSI including MRSA (300 mg IV or 450 mg PO q12h)"
            }
          ],
          "comments": [
            "All ~100% oral bioavailability"
          ]
        },
        {
          "id": "id2-11",
          "stepNumber": 11,
          "title": "What are the Black Box Warnings for fluoroquinolones?",
          "pageRef": "p.7",
          "subSteps": [
            {
              "id": "11a",
              "content": "Tendon rupture/tendinitis (especially Achilles)"
            },
            {
              "id": "11b",
              "content": "Peripheral neuropathy (may be permanent)"
            },
            {
              "id": "11c",
              "content": "CNS effects: seizures, increased ICP"
            },
            {
              "id": "11d",
              "content": "Aortic aneurysm/dissection"
            },
            {
              "id": "11e",
              "content": "Myasthenia gravis exacerbation (contraindicated)"
            }
          ],
          "comments": [
            "FDA: reserve for serious infections when alternatives unavailable"
          ]
        },
        {
          "id": "id2-12",
          "stepNumber": 12,
          "title": "What are other adverse effects and interactions of fluoroquinolones?",
          "pageRef": "p.7",
          "subSteps": [
            {
              "id": "12a",
              "content": "QTc prolongation (greatest with moxifloxacin)"
            },
            {
              "id": "12b",
              "content": "Photosensitivity, GI upset"
            },
            {
              "id": "12c",
              "content": "Dysglycemia, C. difficile"
            },
            {
              "id": "12d",
              "content": "Divalent/trivalent cations: separate by 2-6 hours (antacids, Ca, Fe, Zn)"
            }
          ],
          "comments": [
            "Avoid in pregnancy/children (cartilage damage)"
          ]
        },
        {
          "id": "id2-13",
          "stepNumber": 13,
          "title": "What are the aminoglycosides and their characteristics?",
          "pageRef": "p.7-9",
          "subSteps": [
            {
              "id": "13a",
              "content": "MOA: Bind 30S ribosomal subunit, inhibit protein synthesis"
            },
            {
              "id": "13b",
              "content": "Concentration-dependent bactericidal (PK/PD: Cmax/MIC 8-10)"
            },
            {
              "id": "13c",
              "content": "Spectrum: Gram-negatives (including Pseudomonas)"
            },
            {
              "id": "13d",
              "content": "NO activity: Anaerobes (require oxygen for uptake)"
            }
          ],
          "comments": [
            "Always use in combination",
            "Synergy with beta-lactams for Gram(+)"
          ]
        },
        {
          "id": "id2-14",
          "stepNumber": 14,
          "title": "What is extended-interval dosing for aminoglycosides?",
          "pageRef": "p.8-9",
          "subSteps": [
            {
              "id": "14a",
              "content": "Gentamicin/Tobramycin: 5-7 mg/kg q24h"
            },
            {
              "id": "14b",
              "content": "Amikacin: 15-20 mg/kg q24h"
            },
            {
              "id": "14c",
              "content": "Advantages: enhanced efficacy, reduced toxicity, convenient"
            },
            {
              "id": "14d",
              "content": "Monitoring: random level 6-14 hours post-dose"
            }
          ],
          "comments": [
            "Preferred for most indications",
            "Traditional dosing for endocarditis, pregnancy"
          ]
        },
        {
          "id": "id2-15",
          "stepNumber": 15,
          "title": "What are the adverse effects of aminoglycosides?",
          "pageRef": "p.9",
          "subSteps": [
            {
              "id": "15a",
              "content": "Nephrotoxicity (10-25%): usually reversible, monitor SCr/BUN"
            },
            {
              "id": "15b",
              "content": "Ototoxicity: vestibular (vertigo) and cochlear (hearing loss, often permanent)"
            },
            {
              "id": "15c",
              "content": "Neuromuscular blockade: rare"
            },
            {
              "id": "15d",
              "content": "Risk factors: prolonged therapy, high levels, concurrent nephro/ototoxins"
            }
          ],
          "comments": [
            "Avoid concurrent vancomycin, NSAIDs, contrast"
          ]
        },
        {
          "id": "id2-16",
          "stepNumber": 16,
          "title": "What are the macrolides and their spectrum?",
          "pageRef": "p.9-10",
          "subSteps": [
            {
              "id": "16a",
              "content": "MOA: Bind 50S ribosomal subunit, inhibit protein synthesis"
            },
            {
              "id": "16b",
              "content": "Bacteriostatic (bactericidal at high concentrations)"
            },
            {
              "id": "16c",
              "content": "Spectrum: Gram(+), atypicals (Mycoplasma, Chlamydia, Legionella)"
            },
            {
              "id": "16d",
              "content": "Some Gram(-): H. influenzae (azithromycin)"
            }
          ]
        },
        {
          "id": "id2-17",
          "stepNumber": 17,
          "title": "What are the individual macrolide agents?",
          "pageRef": "p.9-10",
          "subSteps": [
            {
              "id": "17a",
              "content": "Erythromycin: 250-500 mg q6h, poor GI tolerance, significant drug interactions"
            },
            {
              "id": "17b",
              "content": "Clarithromycin: 250-500 mg q12h, better tolerated, strong CYP3A4 inhibitor"
            },
            {
              "id": "17c",
              "content": "Azithromycin: 500 mg x1 then 250 mg q24h x4d (Z-Pak), long half-life (68h)"
            },
            {
              "id": "17d",
              "content": "Azithromycin: once-daily, short courses, fewer interactions, best GI tolerance"
            }
          ]
        },
        {
          "id": "id2-18",
          "stepNumber": 18,
          "title": "What are the adverse effects of macrolides?",
          "pageRef": "p.10",
          "subSteps": [
            {
              "id": "18a",
              "content": "GI: nausea, vomiting, diarrhea (motilin receptor agonist)"
            },
            {
              "id": "18b",
              "content": "QTc prolongation: all macrolides (greatest with azithromycin)"
            },
            {
              "id": "18c",
              "content": "Hepatotoxicity: rare cholestatic hepatitis"
            },
            {
              "id": "18d",
              "content": "CYP3A4 inhibition: erythro > clarithro >> azithro"
            }
          ],
          "comments": [
            "FDA warning: increased CV death risk with azithromycin"
          ]
        },
        {
          "id": "id2-19",
          "stepNumber": 19,
          "title": "What is doxycycline and its uses?",
          "pageRef": "p.11-12",
          "subSteps": [
            {
              "id": "19a",
              "content": "Tetracycline: binds 30S ribosomal subunit, bacteriostatic"
            },
            {
              "id": "19b",
              "content": "Dosing: 100 mg PO/IV q12h, 90-100% oral bioavailability"
            },
            {
              "id": "19c",
              "content": "Spectrum: Broad (Gram+/-, atypicals, rickettsiae, MRSA)"
            },
            {
              "id": "19d",
              "content": "Uses: CAP, tick-borne diseases, ABSSSI, acne, malaria prophylaxis"
            }
          ],
          "comments": [
            "Drug of choice for tick-borne illnesses (Lyme, RMSF, ehrlichiosis)"
          ]
        },
        {
          "id": "id2-20",
          "stepNumber": 20,
          "title": "What is tigecycline and its characteristics?",
          "pageRef": "p.12",
          "subSteps": [
            {
              "id": "20a",
              "content": "Glycylcycline (tetracycline derivative)"
            },
            {
              "id": "20b",
              "content": "Broad spectrum: MRSA, VRE, ESBL, anaerobes"
            },
            {
              "id": "20c",
              "content": "NO activity: Pseudomonas, Proteus"
            },
            {
              "id": "20d",
              "content": "Dosing: 100 mg IV x1, then 50 mg IV q12h"
            }
          ],
          "comments": [
            "BLACK BOX: increased mortality vs comparators - reserve for limited options",
            "Very high nausea/vomiting"
          ]
        },
        {
          "id": "id2-21",
          "stepNumber": 21,
          "title": "What are the adverse effects of tetracyclines?",
          "pageRef": "p.12",
          "subSteps": [
            {
              "id": "21a",
              "content": "GI: nausea, vomiting, esophagitis (take with water, stay upright)"
            },
            {
              "id": "21b",
              "content": "Photosensitivity: severe sunburn with minimal sun"
            },
            {
              "id": "21c",
              "content": "Tooth discoloration: permanent in children <8 years"
            },
            {
              "id": "21d",
              "content": "Chelation: separate from Ca, Fe, Mg, Al by 2-3 hours"
            }
          ],
          "comments": [
            "Contraindicated: pregnancy, breastfeeding, children <8 years"
          ]
        },
        {
          "id": "id2-22",
          "stepNumber": 22,
          "title": "What is clindamycin and its spectrum?",
          "pageRef": "p.13",
          "subSteps": [
            {
              "id": "22a",
              "content": "Inhibits protein synthesis (50S), bacteriostatic"
            },
            {
              "id": "22b",
              "content": "Spectrum: Gram(+) cocci (MRSA), anaerobes (B. fragilis)"
            },
            {
              "id": "22c",
              "content": "NO activity: Gram(-), Enterococcus"
            },
            {
              "id": "22d",
              "content": "Dosing: 150-450 mg PO q6-8h, 600-900 mg IV q8h"
            }
          ],
          "comments": [
            "Suppresses toxin production",
            "Excellent bone penetration"
          ]
        },
        {
          "id": "id2-23",
          "stepNumber": 23,
          "title": "What is TMP/SMX and its characteristics?",
          "pageRef": "p.13-14",
          "subSteps": [
            {
              "id": "23a",
              "content": "Sequential blockade of folic acid synthesis, bactericidal"
            },
            {
              "id": "23b",
              "content": "Spectrum: MRSA, MSSA, Gram(-), PCP, Stenotrophomonas"
            },
            {
              "id": "23c",
              "content": "Dosing: 1 DS tablet PO q12h (standard), higher for PCP"
            },
            {
              "id": "23d",
              "content": "Uses: UTI (first-line), MRSA ABSSSI, PCP treatment/prophylaxis"
            }
          ]
        },
        {
          "id": "id2-24",
          "stepNumber": 24,
          "title": "What are the adverse effects of TMP/SMX?",
          "pageRef": "p.14",
          "subSteps": [
            {
              "id": "24a",
              "content": "Hyperkalemia: trimethoprim = K-sparing diuretic"
            },
            {
              "id": "24b",
              "content": "Nephrotoxicity: \u2191SCr (blocks tubular secretion, not true damage)"
            },
            {
              "id": "24c",
              "content": "Rash: common (3-5%), Stevens-Johnson in severe cases"
            },
            {
              "id": "24d",
              "content": "Drug interactions: warfarin (\u2191INR), methotrexate, phenytoin"
            }
          ],
          "comments": [
            "Monitor K+ and SCr during therapy"
          ]
        },
        {
          "id": "id2-25",
          "stepNumber": 25,
          "title": "What is metronidazole and its uses?",
          "pageRef": "p.14",
          "subSteps": [
            {
              "id": "25a",
              "content": "Disrupts DNA, bactericidal against anaerobes"
            },
            {
              "id": "25b",
              "content": "Spectrum: Anaerobes (Bacteroides, Clostridium including C. diff)"
            },
            {
              "id": "25c",
              "content": "Uses: C. diff, intra-abdominal infections, bacterial vaginosis, trichomoniasis"
            },
            {
              "id": "25d",
              "content": "Dosing: 500 mg PO/IV q8h (C. diff), 2g x1 (trich)"
            }
          ],
          "comments": [
            "Excellent CNS penetration"
          ]
        },
        {
          "id": "id2-26",
          "stepNumber": 26,
          "title": "What are the adverse effects of metronidazole?",
          "pageRef": "p.14",
          "subSteps": [
            {
              "id": "26a",
              "content": "Disulfiram-like reaction: severe with alcohol (avoid during + 3 days after)"
            },
            {
              "id": "26b",
              "content": "Metallic taste: very common"
            },
            {
              "id": "26c",
              "content": "Peripheral neuropathy: prolonged use >2 weeks"
            },
            {
              "id": "26d",
              "content": "Drug interactions: warfarin (\u2191INR), lithium"
            }
          ]
        },
        {
          "id": "id2-27",
          "stepNumber": 27,
          "title": "What is rifampin and its uses?",
          "pageRef": "p.15",
          "subSteps": [
            {
              "id": "27a",
              "content": "Inhibits bacterial RNA polymerase, bactericidal"
            },
            {
              "id": "27b",
              "content": "ALWAYS combination therapy (rapid resistance if alone)"
            },
            {
              "id": "27c",
              "content": "Uses: TB, Staph prosthetic joint infections, MRSA bacteremia (adjunct)"
            },
            {
              "id": "27d",
              "content": "Meningitis prophylaxis: N. meningitidis, H. influenzae"
            }
          ]
        },
        {
          "id": "id2-28",
          "stepNumber": 28,
          "title": "What are the adverse effects of rifampin?",
          "pageRef": "p.15",
          "subSteps": [
            {
              "id": "28a",
              "content": "Orange discoloration: urine, tears, sweat (warn patients, stains contacts)"
            },
            {
              "id": "28b",
              "content": "Hepatotoxicity: monitor LFTs"
            },
            {
              "id": "28c",
              "content": "Potent CYP3A4 inducer: decreases levels of many drugs"
            },
            {
              "id": "28d",
              "content": "Decreases: oral contraceptives, warfarin, protease inhibitors"
            }
          ],
          "comments": [
            "Requires alternative contraception",
            "Excellent biofilm penetration"
          ]
        },
        {
          "id": "id2-29",
          "stepNumber": 29,
          "title": "What is nitrofurantoin and its uses?",
          "pageRef": "p.15",
          "subSteps": [
            {
              "id": "29a",
              "content": "Damages bacterial DNA, bactericidal at urinary concentrations"
            },
            {
              "id": "29b",
              "content": "Spectrum: E. coli, Enterococcus, S. saprophyticus"
            },
            {
              "id": "29c",
              "content": "NO activity: Pseudomonas, Proteus, Serratia, many Klebsiella"
            },
            {
              "id": "29d",
              "content": "Use: Uncomplicated UTI (cystitis) ONLY, NOT pyelonephritis"
            }
          ],
          "comments": [
            "Dosing: 100 mg PO q12h x5-7 days"
          ]
        },
        {
          "id": "id2-30",
          "stepNumber": 30,
          "title": "What are the adverse effects and contraindications of nitrofurantoin?",
          "pageRef": "p.15",
          "subSteps": [
            {
              "id": "30a",
              "content": "Pulmonary toxicity: acute pneumonitis or chronic fibrosis (risk \u2191 with >6 months)"
            },
            {
              "id": "30b",
              "content": "Peripheral neuropathy: especially with renal impairment"
            },
            {
              "id": "30c",
              "content": "Contraindications: CrCl <30 mL/min, pregnancy at term, G6PD deficiency"
            },
            {
              "id": "30d",
              "content": "Take with food to reduce GI upset"
            }
          ],
          "comments": [
            "Only achieves therapeutic levels in urine",
            "Monitor for pulmonary symptoms during long-term use"
          ]
        },
        {
          "id": "id2-31",
          "stepNumber": 31,
          "title": "What are the newer lipoglycopeptides?",
          "pageRef": "p.3",
          "subSteps": [
            {
              "id": "31a",
              "content": "Telavancin (Vibativ): 10 mg/kg IV q24h, MRSA skin infections, HAP"
            },
            {
              "id": "31b",
              "content": "Dalbavancin (Dalvance): 1500 mg x1 OR 1000mg + 500mg week later"
            },
            {
              "id": "31c",
              "content": "Oritavancin (Orbactiv): 1200 mg single dose"
            },
            {
              "id": "31d",
              "content": "Advantage: Single-dose therapy for ABSSSI"
            }
          ],
          "comments": [
            "Ultra-long half-life",
            "Outpatient parenteral therapy without IV access maintenance"
          ]
        },
        {
          "id": "id2-32",
          "stepNumber": 32,
          "title": "What is tedizolid?",
          "pageRef": "p.5",
          "subSteps": [
            {
              "id": "32a",
              "content": "Second-generation oxazolidinone"
            },
            {
              "id": "32b",
              "content": "Dosing: 200 mg PO/IV q24h x6 days"
            },
            {
              "id": "32c",
              "content": "Indication: ABSSSI"
            },
            {
              "id": "32d",
              "content": "Advantages: Lower myelosuppression, once-daily dosing"
            }
          ]
        },
        {
          "id": "id2-33",
          "stepNumber": 33,
          "title": "What is amikacin and when is it used?",
          "pageRef": "p.8",
          "subSteps": [
            {
              "id": "33a",
              "content": "Aminoglycoside resistant to many modifying enzymes"
            },
            {
              "id": "33b",
              "content": "Reserve for resistant organisms"
            },
            {
              "id": "33c",
              "content": "Dosing: 15-20 mg/kg q24h"
            },
            {
              "id": "33d",
              "content": "Same spectrum and toxicity as gentamicin/tobramycin"
            }
          ]
        },
        {
          "id": "id2-34",
          "stepNumber": 34,
          "title": "What are the newer tetracyclines?",
          "pageRef": "p.12",
          "subSteps": [
            {
              "id": "34a",
              "content": "Eravacycline (Xerava): complicated intra-abdominal, 1 mg/kg IV q12h"
            },
            {
              "id": "34b",
              "content": "Omadacycline (Nuzyra): CAP, ABSSSI, oral and IV formulations"
            },
            {
              "id": "34c",
              "content": "Advantages: less nausea than tigecycline, active against some tigecycline-resistant"
            }
          ]
        },
        {
          "id": "id2-35",
          "stepNumber": 35,
          "title": "What C. difficile risk does clindamycin have?",
          "pageRef": "p.13",
          "comments": [
            "High risk for C. difficile infection (10-30%)",
            "OR 2.86 for C. diff in meta-analysis",
            "Consider alternatives when possible",
            "Good for: bone infections, ABSSSI, aspiration pneumonia, toxin suppression"
          ]
        }
      ]
    },
    {
      "id": "treatment-guidelines",
      "name": "Selected Treatment Guidelines",
      "shortName": "Treatment Guidelines",
      "totalSteps": 35,
      "steps": [
        {
          "id": "tg-1",
          "stepNumber": 1,
          "title": "What are the usual organisms in skin and soft tissue infections?",
          "pageRef": "p.1",
          "comments": [
            "S. aureus (most common)",
            "S. pyogenes (Group A Strep)",
            "Common disease states: Impetigo, Erysipelas (think strep!), Cellulitis"
          ]
        },
        {
          "id": "tg-2",
          "stepNumber": 2,
          "title": "What is the treatment for S. pyogenes?",
          "pageRef": "p.1",
          "subSteps": [
            {
              "id": "2a",
              "content": "Drug of choice: Penicillin (nearly universally susceptible)"
            },
            {
              "id": "2b",
              "content": "Narrow spectrum therapy"
            },
            {
              "id": "2c",
              "content": "Most Gram(+) agents cover (EXCEPT doxycycline)"
            },
            {
              "id": "2d",
              "content": "Clindamycin has resistance issues"
            }
          ]
        },
        {
          "id": "tg-3",
          "stepNumber": 3,
          "title": "When should MRSA be covered in cellulitis?",
          "pageRef": "p.1",
          "comments": [
            "Routine coverage: purulent cellulitis and abscesses",
            "Usually NOT warranted in systemic infections without these characteristics",
            "Increase in community-acquired (CA) MRSA"
          ]
        },
        {
          "id": "tg-4",
          "stepNumber": 4,
          "title": "What are the oral options for S. aureus?",
          "pageRef": "p.1-2",
          "subSteps": [
            {
              "id": "4a",
              "content": "MSSA: Cephalexin, Amoxicillin/clavulanate, Dicloxacillin"
            },
            {
              "id": "4b",
              "content": "MRSA: TMP/SMX, Doxycycline, Linezolid"
            },
            {
              "id": "4c",
              "content": "All cover S. pyogenes EXCEPT doxycycline"
            },
            {
              "id": "4d",
              "content": "Follow up at 24-48 hours prudent"
            }
          ]
        },
        {
          "id": "tg-5",
          "stepNumber": 5,
          "title": "What is the treatment for severe cellulitis?",
          "pageRef": "p.2",
          "subSteps": [
            {
              "id": "5a",
              "content": "Defined by: failure of oral abx + debridement, systemic symptoms"
            },
            {
              "id": "5b",
              "content": "MSSA/Strep only: Nafcillin or Cefazolin"
            },
            {
              "id": "5c",
              "content": "MRSA: Vancomycin or Daptomycin"
            },
            {
              "id": "5d",
              "content": "Duration: 5-7 days (guideline: 7 days), up to 14 days if started IV"
            }
          ]
        },
        {
          "id": "tg-6",
          "stepNumber": 6,
          "title": "What is the treatment for animal bites?",
          "pageRef": "p.3",
          "subSteps": [
            {
              "id": "6a",
              "content": "Must cover Pasteurella multocida (has beta-lactamase)"
            },
            {
              "id": "6b",
              "content": "DOC: Amoxicillin/clavulanic acid"
            },
            {
              "id": "6c",
              "content": "IV: Ampicillin/sulbactam or 3G cephalosporin"
            },
            {
              "id": "6d",
              "content": "Alternatives (PCN allergy): Doxycycline, Moxifloxacin"
            }
          ],
          "comments": [
            "Cat bites more likely to get infected than dog bites",
            "Average 5 organisms per bite"
          ]
        },
        {
          "id": "tg-7",
          "stepNumber": 7,
          "title": "What is the treatment for diabetic foot ulcers?",
          "pageRef": "p.3",
          "subSteps": [
            {
              "id": "7a",
              "content": "Organisms: S. aureus (MRSA) predominate; Gram(-) in deep ulcers"
            },
            {
              "id": "7b",
              "content": "Uninfected ulcers: do NOT treat"
            },
            {
              "id": "7c",
              "content": "Empiric: Vancomycin +/- Ceftriaxone (varies)"
            },
            {
              "id": "7d",
              "content": "Duration: 1-2 wk mild; 2-4 wk moderate; 4-6 wk if bone involvement"
            }
          ],
          "comments": [
            "Do not treat until ulcer heals - just until infection resolves"
          ]
        },
        {
          "id": "tg-8",
          "stepNumber": 8,
          "title": "What is the treatment for uncomplicated cystitis?",
          "pageRef": "p.4",
          "subSteps": [
            {
              "id": "8a",
              "content": "Target: E. coli (based on local susceptibility)"
            },
            {
              "id": "8b",
              "content": "3 days: TMP/SMX, Fluoroquinolones (not moxifloxacin)"
            },
            {
              "id": "8c",
              "content": "5 days: Nitrofurantoin"
            },
            {
              "id": "8d",
              "content": "7 days: Beta-lactams"
            }
          ]
        },
        {
          "id": "tg-9",
          "stepNumber": 9,
          "title": "What is fosfomycin and its use?",
          "pageRef": "p.4",
          "subSteps": [
            {
              "id": "9a",
              "content": "MOA: Inhibits enolpyruvate transferase (peptidoglycan synthesis)"
            },
            {
              "id": "9b",
              "content": "Dosing: 3g PO x1 for cystitis"
            },
            {
              "id": "9c",
              "content": "Safe for pregnancy"
            },
            {
              "id": "9d",
              "content": "Recent evidence: inferior to nitrofurantoin, consider second-line"
            }
          ]
        },
        {
          "id": "tg-10",
          "stepNumber": 10,
          "title": "What defines a complicated UTI?",
          "pageRef": "p.4",
          "subSteps": [
            {
              "id": "10a",
              "content": "Structural/functional abnormality: obstruction, foreign body, males"
            },
            {
              "id": "10b",
              "content": "Pyelonephritis"
            },
            {
              "id": "10c",
              "content": "Recent guidelines: extending beyond the bladder"
            },
            {
              "id": "10d",
              "content": "Extends duration to 7+ days"
            }
          ]
        },
        {
          "id": "tg-11",
          "stepNumber": 11,
          "title": "What is the treatment for community-acquired pyelonephritis?",
          "pageRef": "p.4",
          "subSteps": [
            {
              "id": "11a",
              "content": "Oral: FQ, TMP/SMX (first-line)"
            },
            {
              "id": "11b",
              "content": "NOT appropriate: Nitrofurantoin, Fosfomycin (inadequate tissue levels)"
            },
            {
              "id": "11c",
              "content": "IV: FQ, Aminoglycosides, Ceftriaxone, Carbapenems (if resistant)"
            },
            {
              "id": "11d",
              "content": "Duration: 7-14 days (7 days standard, even with bacteremia)"
            }
          ]
        },
        {
          "id": "tg-12",
          "stepNumber": 12,
          "title": "What are 'The Big 6' CAP bacterial pathogens?",
          "pageRef": "p.6",
          "subSteps": [
            {
              "id": "12a",
              "content": "S. pneumoniae, H. influenzae, M. catarrhalis"
            },
            {
              "id": "12b",
              "content": "M. pneumoniae, C. pneumoniae, L. pneumophilia"
            },
            {
              "id": "12c",
              "content": "Others: S. aureus (CA-MRSA, post-influenza)"
            },
            {
              "id": "12d",
              "content": "Anaerobes: only cover for empyema, lung abscess"
            }
          ]
        },
        {
          "id": "tg-13",
          "stepNumber": 13,
          "title": "What is outpatient treatment for CAP?",
          "pageRef": "p.6-7",
          "subSteps": [
            {
              "id": "13a",
              "content": "Healthy adults: Amoxicillin or Doxycycline (macrolides NO longer recommended)"
            },
            {
              "id": "13b",
              "content": "With comorbidities/recent abx: Beta-lactam + (Doxy or Macrolide)"
            },
            {
              "id": "13c",
              "content": "Alternative: Respiratory fluoroquinolone"
            },
            {
              "id": "13d",
              "content": "Duration: minimum 5 days (some data: 3 days sufficient)"
            }
          ]
        },
        {
          "id": "tg-14",
          "stepNumber": 14,
          "title": "What is inpatient treatment for CAP?",
          "pageRef": "p.7",
          "subSteps": [
            {
              "id": "14a",
              "content": "Non-severe (floor): Beta-lactam + (Doxy or Macrolide) OR Respiratory FQ"
            },
            {
              "id": "14b",
              "content": "Severe (ICU): Same as above, tetracyclines not listed"
            },
            {
              "id": "14c",
              "content": "Consider vancomycin (not guideline recommendation)"
            },
            {
              "id": "14d",
              "content": "Can transition to oral when stable"
            }
          ]
        },
        {
          "id": "tg-15",
          "stepNumber": 15,
          "title": "What happened to HCAP?",
          "pageRef": "p.7",
          "comments": [
            "HCAP (healthcare-associated pneumonia) went away in 2016",
            "Now: previous microbiology is primary driver for MRSA, Pseudomonas coverage",
            "Recent hospitalization/SNF + broad-spectrum abx also considered",
            "Detailed history, personalized approach is key"
          ]
        },
        {
          "id": "tg-16",
          "stepNumber": 16,
          "title": "What are the organisms and empiric therapy for HAP/VAP?",
          "pageRef": "p.7-8",
          "subSteps": [
            {
              "id": "16a",
              "content": "Organisms: S. aureus (MRSA), P. aeruginosa, Enterobacteriaceae, ESBL"
            },
            {
              "id": "16b",
              "content": "Empiric: Vancomycin or Linezolid + Anti-pseudomonal beta-lactam"
            },
            {
              "id": "16c",
              "content": "Plus/minus: Anti-pseudomonal FQ or Aminoglycoside"
            },
            {
              "id": "16d",
              "content": "De-escalate! Duration: 7 days (historically 14-21)"
            }
          ]
        },
        {
          "id": "tg-17",
          "stepNumber": 17,
          "title": "What is COVID-19 outpatient treatment?",
          "pageRef": "p.9",
          "subSteps": [
            {
              "id": "17a",
              "content": "Goal: Stop progression to hospital/death"
            },
            {
              "id": "17b",
              "content": "Nirmatrelvir/ritonavir (Paxlovid): protease inhibitor, MANY drug interactions"
            },
            {
              "id": "17c",
              "content": "Remdesivir: RNA polymerase inhibitor, IV only"
            },
            {
              "id": "17d",
              "content": "Molnupiravir: contraindication in pregnant/pregnancy potential"
            }
          ]
        },
        {
          "id": "tg-18",
          "stepNumber": 18,
          "title": "What is COVID-19 hospitalized treatment?",
          "pageRef": "p.9",
          "subSteps": [
            {
              "id": "18a",
              "content": "Room air (moderate): supportive care, consider outpatient therapies if high risk"
            },
            {
              "id": "18b",
              "content": "Hypoxia (moderate-severe): Remdesivir, dexamethasone, +/- tocilizumab or baricitinib"
            },
            {
              "id": "18c",
              "content": "Mechanical ventilation (critical): Dexamethasone, tocilizumab or baricitinib"
            }
          ]
        },
        {
          "id": "tg-19",
          "stepNumber": 19,
          "title": "What is influenza treatment?",
          "pageRef": "p.9",
          "comments": [
            "Vaccination is key (less efficacious than COVID vaccines)",
            "Treatment modestly effective, must start early",
            "Oseltamivir: mainstay, 5 days (longer for critically ill)",
            "Baloxavir: single dose, recent approval"
          ]
        },
        {
          "id": "tg-20",
          "stepNumber": 20,
          "title": "When should acute bronchitis be treated with antibiotics?",
          "pageRef": "p.10",
          "subSteps": [
            {
              "id": "20a",
              "content": "Vast majority viral - antimicrobials NOT warranted"
            },
            {
              "id": "20b",
              "content": "Exceptions: B. pertussis (macrolides), Influenza (oseltamivir)"
            },
            {
              "id": "20c",
              "content": "Mycoplasma/Chlamydia: macrolide, doxycycline"
            },
            {
              "id": "20d",
              "content": "Symptomatic treatment is mainstay"
            }
          ]
        },
        {
          "id": "tg-21",
          "stepNumber": 21,
          "title": "What is treatment for COPD exacerbation?",
          "pageRef": "p.10",
          "subSteps": [
            {
              "id": "21a",
              "content": "Who gets abx: 3 cardinal symptoms (dyspnea, sputum volume, purulence) or 2 if purulence"
            },
            {
              "id": "21b",
              "content": "Oral: Amoxicillin/clavulanate, Doxycycline, Macrolides, Respiratory FQs"
            },
            {
              "id": "21c",
              "content": "IV: For risk factors (comorbidities, severe COPD, frequent exacerbations)"
            },
            {
              "id": "21d",
              "content": "Duration: 5-7 days"
            }
          ]
        },
        {
          "id": "tg-22",
          "stepNumber": 22,
          "title": "When should sinusitis be treated with antibiotics?",
          "pageRef": "p.10",
          "subSteps": [
            {
              "id": "22a",
              "content": "Usually viral - only treat if:"
            },
            {
              "id": "22b",
              "content": "1. Persistence >10 days with no improvement"
            },
            {
              "id": "22c",
              "content": "2. Severe symptoms (fever >39 + purulent discharge/facial pain \u22653-4 days)"
            },
            {
              "id": "22d",
              "content": "3. Worsening symptoms"
            },
            {
              "id": "22e",
              "content": "Treatment: Amoxicillin/clavulanate, Doxycycline, FQ; Duration: 5-7 days"
            }
          ]
        },
        {
          "id": "tg-23",
          "stepNumber": 23,
          "title": "What are the empiric regimens for bacterial meningitis by age?",
          "pageRef": "p.11",
          "subSteps": [
            {
              "id": "23a",
              "content": "<1 month: Ampicillin + gentamicin (or cefotaxime, avoid ceftriaxone)"
            },
            {
              "id": "23b",
              "content": "1-23 months & 2-50 years: Vancomycin + 3G cephalosporin"
            },
            {
              "id": "23c",
              "content": ">50 years: Vancomycin + 3G cephalosporin + ampicillin (for Listeria)"
            },
            {
              "id": "23d",
              "content": "Dexamethasone 10mg q6h x4 days (give PRIOR to first abx)"
            }
          ]
        },
        {
          "id": "tg-24",
          "stepNumber": 24,
          "title": "What antibiotics have good CNS penetration?",
          "pageRef": "p.11",
          "subSteps": [
            {
              "id": "24a",
              "content": "Sufficient: 3rd/4th gen cephalosporins, Penicillin, Ampicillin"
            },
            {
              "id": "24b",
              "content": "Vancomycin, TMP/SMX, Fluoroquinolones, Metronidazole"
            },
            {
              "id": "24c",
              "content": "Insufficient: Tetracyclines, Aminoglycosides, Polymyxins"
            },
            {
              "id": "24d",
              "content": "Use IV at maximal doses, bactericidal preferred"
            }
          ]
        },
        {
          "id": "tg-25",
          "stepNumber": 25,
          "title": "What is the treatment for Listeria meningitis?",
          "pageRef": "p.11",
          "subSteps": [
            {
              "id": "25a",
              "content": "DOC: Ampicillin (HELPS bug)"
            },
            {
              "id": "25b",
              "content": "Alternatives: TMP/SMX (good efficacy), Meropenem"
            },
            {
              "id": "25c",
              "content": "Gentamicin sometimes added (but 'silly' per notes)"
            },
            {
              "id": "25d",
              "content": "Risk: >50 yo, pregnant, immunocompromised"
            }
          ]
        },
        {
          "id": "tg-26",
          "stepNumber": 26,
          "title": "What is meningitis prophylaxis?",
          "pageRef": "p.12",
          "subSteps": [
            {
              "id": "26a",
              "content": "N. meningitidis: household contacts, oral secretion exposure"
            },
            {
              "id": "26b",
              "content": "Treatment: Ciprofloxacin x1 (alternatives: Rifampin 2d, Ceftriaxone IM)"
            },
            {
              "id": "26c",
              "content": "H. influenzae: everyone in household with unvaccinated children"
            },
            {
              "id": "26d",
              "content": "Treatment: Rifampin"
            }
          ]
        },
        {
          "id": "tg-27",
          "stepNumber": 27,
          "title": "What is the treatment for SBP (spontaneous bacterial peritonitis)?",
          "pageRef": "p.13",
          "subSteps": [
            {
              "id": "27a",
              "content": "Common in cirrhosis \u2192 ascites"
            },
            {
              "id": "27b",
              "content": "Organisms: E. coli, Streptococcus, Klebsiella"
            },
            {
              "id": "27c",
              "content": "Treatment: 3rd generation cephalosporins"
            },
            {
              "id": "27d",
              "content": "Duration: 5-7 days"
            },
            {
              "id": "27e",
              "content": "Prophylaxis (high risk/history): TMP/SMX 5d/wk or Cipro weekly"
            }
          ]
        },
        {
          "id": "tg-28",
          "stepNumber": 28,
          "title": "What is the treatment for intra-abdominal infections?",
          "pageRef": "p.13",
          "subSteps": [
            {
              "id": "28a",
              "content": "Organisms: B. fragilis, E. coli"
            },
            {
              "id": "28b",
              "content": "Community-acquired: Cephalosporin + metronidazole OR Cefoxitin"
            },
            {
              "id": "28c",
              "content": "Nosocomial/critically ill: Cefepime/MTZ, Pip/tazo, Carbapenem"
            },
            {
              "id": "28d",
              "content": "Duration: 4-5 days with source control (guideline recommendation)"
            }
          ]
        },
        {
          "id": "tg-29",
          "stepNumber": 29,
          "title": "What is the current treatment for C. difficile?",
          "pageRef": "p.14",
          "subSteps": [
            {
              "id": "29a",
              "content": "D/C broad-spectrum abx and acid-suppressive agents if possible"
            },
            {
              "id": "29b",
              "content": "Fidaxomicin (superior but costly) or Oral vancomycin"
            },
            {
              "id": "29c",
              "content": "Metronidazole almost never recommended (inferior)"
            },
            {
              "id": "29d",
              "content": "Duration: 10-14 days; recurrence common (consider FMT)"
            }
          ]
        },
        {
          "id": "tg-30",
          "stepNumber": 30,
          "title": "What is the treatment for chlamydia?",
          "pageRef": "p.15",
          "subSteps": [
            {
              "id": "30a",
              "content": "Doxycycline 100 mg PO BID x7 days (first-line per 2021 guidelines)"
            },
            {
              "id": "30b",
              "content": "Azithromycin 1g x1"
            },
            {
              "id": "30c",
              "content": "Doxycycline superior for rectal chlamydia in MSM"
            },
            {
              "id": "30d",
              "content": "Partners: evaluate if sexual contact in last 60 days; abstain x7 days"
            }
          ]
        },
        {
          "id": "tg-31",
          "stepNumber": 31,
          "title": "What is the treatment for gonorrhea?",
          "pageRef": "p.15-16",
          "subSteps": [
            {
              "id": "31a",
              "content": "Uncomplicated: Ceftriaxone 500mg IM x1 (\u2265150kg = 1g)"
            },
            {
              "id": "31b",
              "content": "PLUS Doxycycline 100mg PO x7 days (unless chlamydia ruled out)"
            },
            {
              "id": "31c",
              "content": "Disseminated (septic arthritis, endocarditis): Full-dose 3G ceph IV"
            },
            {
              "id": "31d",
              "content": "Duration depends on site"
            }
          ]
        },
        {
          "id": "tg-32",
          "stepNumber": 32,
          "title": "What is the treatment for syphilis by stage?",
          "pageRef": "p.15",
          "subSteps": [
            {
              "id": "32a",
              "content": "Penicillin preferred for ALL stages"
            },
            {
              "id": "32b",
              "content": "Primary/Secondary: Benzathine penicillin IM x1"
            },
            {
              "id": "32c",
              "content": "Latent (late): 3 doses at 1-week intervals"
            },
            {
              "id": "32d",
              "content": "Neurosyphilis: High-dose IV penicillin"
            }
          ]
        },
        {
          "id": "tg-33",
          "stepNumber": 33,
          "title": "What is the treatment for bacterial vaginosis and trichomoniasis?",
          "pageRef": "p.16",
          "subSteps": [
            {
              "id": "33a",
              "content": "Bacterial vaginosis (anaerobes): Metronidazole x7 days"
            },
            {
              "id": "33b",
              "content": "Trichomoniasis: Metronidazole 2g PO x1 dose"
            },
            {
              "id": "33c",
              "content": "Candidiasis: Fluconazole 150mg x1 (or topicals)"
            }
          ]
        },
        {
          "id": "tg-34",
          "stepNumber": 34,
          "title": "What is the treatment for pelvic inflammatory disease?",
          "pageRef": "p.16",
          "subSteps": [
            {
              "id": "34a",
              "content": "Organisms: N. gonorrhea, C. trachomatis, Gram(-), anaerobes"
            },
            {
              "id": "34b",
              "content": "Empiric: Cefoxitin + doxycycline"
            },
            {
              "id": "34c",
              "content": "Can transition to oral if mild-moderate or clinical response"
            },
            {
              "id": "34d",
              "content": "Cover same organisms"
            }
          ]
        },
        {
          "id": "tg-35",
          "stepNumber": 35,
          "title": "What is the treatment for genital herpes?",
          "pageRef": "p.14-15",
          "subSteps": [
            {
              "id": "35a",
              "content": "First episode: Valacyclovir or Acyclovir x7-10 days"
            },
            {
              "id": "35b",
              "content": "Suppressive (\u22656 episodes/yr): Valacyclovir daily (reduces freq 70-80%)"
            },
            {
              "id": "35c",
              "content": "Episodic: 5-day course"
            },
            {
              "id": "35d",
              "content": "Severe (disseminated): IV acyclovir 5-10 mg/kg q8h, then PO to complete 10d"
            }
          ],
          "comments": [
            "Valacyclovir offers twice-daily dosing",
            "Drugs do NOT eradicate latent virus"
          ]
        }
      ]
    }
  ]
}